GlassScriptPhysician profile
Mark H Mazur
NPI 1245328228
$355.76
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $108.72 | 2019 | |
| Merck Sharp & Dohme LLC | $62.47 | 2019 | |
| Janssen Biotech, INC. | $28.69 | 2019 | |
| Allergan, INC. | $27.97 | 2019 | |
| Grifols USA, LLC | $25.48 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $23.37 | 2019 | |
| Shire North American Group INC | $21.85 | 2019 | |
| Melinta Therapeutics, LLC | $20.09 | 2019 | |
| Viiv Healthcare Company | $19.21 | 2019 | |
| Insmed, INC. | $17.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mazur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.